Please login to the form below

Not currently logged in
Email:
Password:

edivoxetine

This page shows the latest edivoxetine news and features for those working in and with pharma, biotech and healthcare.

Lilly drops tabalumab after lupus joins arthritis on failure list

Lilly drops tabalumab after lupus joins arthritis on failure list

The latest setback marks a barren spell for Lilly in bringing new products to market in the last few years, with a number of late-stage failure including edivoxetine for depression,

Latest news

  • Lilly's stomach cancer drug cleared by FDA Lilly's stomach cancer drug cleared by FDA

    The cancer portfolio is a bright spot for Lilly, which has been plagued by a series of late-stage pipeline failures in the last couple of years, including edivoxetine for depression,

  • Lilly/Boehringer's empagliflozin faces US approval delay Lilly/Boehringer's empagliflozin faces US approval delay

    last year it suffered late-stage setbacks with antidepressant edivoxetine, enzastaurin for lymphoma and tabalumab for rheumatoid arthritis.

  • Lilly feels effects of Cymbalta competition Lilly feels effects of Cymbalta competition

    Cymbalta follow-up edivoxetine failed to meet its objectives in phase III trials as an adjunctive therapy for major depression towards the end of last year and has been discontinued, while

  • Moving parts Moving parts

    Meanwhile, costly phase III failures arrived in the shape of Lilly's depression drug edivoxetine and GlaxoSmithKline's highly anticipated new coronary heart disease drug candidate darapladib, which both flunked

  • First Cymbalta generics approved in the US First Cymbalta generics approved in the US

    cliff. It suffered a major setback in its pipeline earlier this month however when Cymbalta follow-up edivoxetine failed to meet the primary objectives of three late-stage studies.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics